James Crowe | Director
Vanderbilt Vaccine Center

James Crowe, Director, Vanderbilt Vaccine Center

Dr. Crowe is the Director of the Vanderbilt Vaccine Center and the Ann Scott Carell Professor of Pediatrics, Pathology, Microbiology, and Immunology at Vanderbilt University Medical Center. He is a board-certified pediatric infectious diseases physician and viral immunology researcher. His laboratory studies the human immune response to infection for a wide variety of major human pathogens, including many emerging infections. He is an elected member of the National Academy of Medicine and National Academy of Inventors, is an ISI Highly Cited Researcher, and has received numerous investigator awards. He is also Founder of the biotech company IDBiologics and Chairman and CEO of the nonprofit Global Pandemic Prevention and Biodefense Center, home of the AHEAD100 initiative to discover and stockpile human monoclonal antibodies for the 100 most likely causes of future epidemics.

Appearances:



Pre-Congress Workshops - Monday 1st April @ 10:00

GLOBAL HEALTH mABs [M2] Public-Private collaboration for accessible infectious disease mAbs in LMICs

Public-Private collaboration for accessible infectious disease mAbs in LMICs

 

There are significant gaps in monoclonal antibodies (mAbs) access and availability in low- and middle-income countries (LMICs). The highest burden populations for a growing number of licensed mAbs are not benefiting from this class of innovations. Prophylactic, long acting mAbs offer a viable alternative and complementary approach to vaccines in protecting against infections of critical importance in LMICs, but the impact of this established modality may not be realized. Viable business models, commercial incentives and pathways to afford access are currently not in place. Public-Private collaboration will likely be needed to bridge this gap.

 

Co-organized by: IAVI, Medicines Patent Pool (MPP), Unitaid and Wellcome

 

Goal of session: To foster mAb developer engagement to understand the barriers and define the incentives and enablers that would facilitate affordable access to mAbs in LMICs.

Target audience: Participants in the World Vaccine Congress, in particular industry stakeholders working in the mAbs field and broader stakeholders with expertise or interest in various aspects related to the development, manufacturing, supply, regulation, and procurement of monoclonal antibodies.

 

10:00 Introduction

Shelly Malhotra, Executive Director, Global Access, IAVI

 

10:20 Panel: Challenges and opportunities: What are the barriers and unique considerations for mAbs accessibility/availability in LMICs? What advancements have recently been achieved and how can they be further leveraged for infectious disease mAbs?

 

Moderator: Carmen Pérez Casas, Strategy Senior Lead/PPPR Head, Unitaid 

 

11:20 Panel: Industry perspectives on a path towards access and the role of global health stakeholders

 

Moderator: Esteban Burrone, MPP

 

12:20 Wrap up/Closing remarks

Pete Gardner, Wellcome

Day 2 - Wednesday 3rd April @ 09:10

What is the burden and uptake for RSV vaccines?

  • Updates, epidemiology and vaccine fatigue
  • What is the role of mAbs and vaccines for RSV protection?
  • How to we ensure better global health accessibility of RSV vaccines?

Day 2 - Wednesday 3rd April @ 10:25

Advances in the technologies used to study human B-cell repertoires

last published: 29/Mar/24 09:06 GMT

back to speakers